Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

CD1a promotes systemic manifestations of skin inflammation.

Hardman CS. et al, (2022), Nature communications, 13

Pre-existing asthma as a comorbidity does not modify cytokine responses and severity of COVID-19

Luo J. et al, (2021), Allergy, Asthma & Clinical Immunology, 17

Identification of immune correlates of fatal outcomes in critically ill COVID-19 patients

Youngs J. et al, (2021), PLOS Pathogens, 17, e1009804 - e1009804

CD1a selectively captures endogenous cellular lipids that broadly block T cell response.

Cotton RN. et al, (2021), The Journal of experimental medicine, 218

Role of regulatory T cells in psoriasis pathogenesis and treatment.

Nussbaum L. et al, (2021), The British journal of dermatology, 184, 14 - 24

Re-evaluation of human BDCA-2+ DC during acute sterile skin inflammation

Chen Y-L. et al, (2020), The Journal of Experimental Medicine, 217

Resistance to apoptosis underpins the corticosteroid insensitivity of group 2 innate lymphoid cells.

Luo J. et al, (2019), The Journal of allergy and clinical immunology, 144, 1722 - 1726.e10

Fevipiprant, a selective prostaglandin D2 receptor 2 antagonist, inhibits human group 2 innate lymphoid cell aggregation and function.

Hardman C. et al, (2019), The Journal of allergy and clinical immunology, 143, 2329 - 2333

CD1a presentation of endogenous antigens by group 2 innate lymphoid cells

Hardman CS. et al, (2017), Science Immunology, 2

Load More